[PDF][PDF] A high profile review on new oral clotting factor Xa inhibitor: betrixaban
N Patadiya, R Dumpala - Eur J Pharm Med Res, 2021 - researchgate.net
… efficacy the novel anticoagulants are required. New agents like enoxaparin, apixaban and
… [1] Betrixaben is approved by FDA in class of clotting factor Xa inhibitor. Betrixaban became …
… [1] Betrixaben is approved by FDA in class of clotting factor Xa inhibitor. Betrixaban became …
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind …
… In this randomised, double-blind, phase 2 dose-finding study, we compared asundexian
20 mg or 50 mg once daily with apixaban 5 mg twice daily in patients aged 45 years or older …
20 mg or 50 mg once daily with apixaban 5 mg twice daily in patients aged 45 years or older …
[HTML][HTML] News at XI: moving beyond factor Xa inhibitors
JC Fredenburgh, JI Weitz - Journal of Thrombosis and Haemostasis, 2023 - Elsevier
… new agents, this article describes the unmet needs in oral anticoagulation therapy, explains
why FXI is a promising target for new oral … For example, rivaroxaban and apixaban were less …
why FXI is a promising target for new oral … For example, rivaroxaban and apixaban were less …
Apixaban, an orally available anticoagulant, inhibits SARS-CoV-2 replication and its major protease in a non-competitive way
OA Chaves, CQ Sacramento… - Journal of Molecular …, 2022 - academic.oup.com
The severe coronavirus disease 2019 (COVID-19) is associated with coagulopathy.
Anticoagulants, such as low-molecular-weight heparin, warfarin, thrombin inhibitors, and factor Xa (…
Anticoagulants, such as low-molecular-weight heparin, warfarin, thrombin inhibitors, and factor Xa (…
[HTML][HTML] Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa
S Heitmeier, M Visser, A Tersteegen… - Journal of Thrombosis …, 2022 - Elsevier
… However, apixaban significantly increased bleeding time compared to aspirin and ticagrelor
… asundexian, an oral, direct, potent, and selective FXIa inhibitor, represents a novel type of …
… asundexian, an oral, direct, potent, and selective FXIa inhibitor, represents a novel type of …
[HTML][HTML] Factor Xa inhibitors in clinical practice: Comparison of pharmacokinetic profiles
E Goto, S Horinaka, T Ishimitsu, T Kato - Drug metabolism and …, 2020 - Elsevier
… -Liquid Anti-Xa assay using calibrator kits for apixaban and … the STA-Liquid Anti-Xa assay
for apixaban, rivaroxaban, and … their similar molecular weights (apixaban, 459.5; rivaroxaban, …
for apixaban, rivaroxaban, and … their similar molecular weights (apixaban, 459.5; rivaroxaban, …
Apixaban single‐dose pharmacokinetics, bioavailability, renal clearance, and pharmacodynamics following intravenous and Oral administration
C Frost, S Garonzik, A Shenker… - Clinical …, 2021 - Wiley Online Library
… of apixaban, a direct factor Xa (FXa) inhibitor approved for multiple indications. Eight healthy
subjects were randomized 3:1 (apixaban:… received 5 mg of oral apixaban or placebo. Blood …
subjects were randomized 3:1 (apixaban:… received 5 mg of oral apixaban or placebo. Blood …
Novel assay based on diluted prothrombin time reflects anticoagulant effects of direct oral factor Xa inhibitors: Results of multicenter study in Japan
M Ieko, K Ohmura, S Naito, M Yoshida, I Sakuma… - Thrombosis …, 2020 - Elsevier
… , selective oral anticoagulants that target thrombin and factor Xa (direct oral Xa inhibitor, DXaI)
… In the present study, the RITG for apixaban did not significantly fluctuate between the peak …
… In the present study, the RITG for apixaban did not significantly fluctuate between the peak …
Engineering and evaluation of FXa bypassing agents that restore hemostasis following Apixaban associated bleeding
W Jankowski, SS Surov, NE Hernandez… - Nature …, 2024 - nature.com
… of more specific, Direct Oral Anticoagulants (DOACs) 3 . Three commonly prescribed DOACs,
rivaroxaban, apixaban, and edoxaban, are factor Xa (FXa) inhibitors 4,5 and have shown a …
rivaroxaban, apixaban, and edoxaban, are factor Xa (FXa) inhibitors 4,5 and have shown a …
Apixaban and rivaroxaban anti-Xa level utilization and associated bleeding events within an academic health system
N Jakowenko, S Nguyen, M Ruegger, A Dinh… - Thrombosis research, 2020 - Elsevier
… Anti-Xa assays can estimate anticoagulant effect for specific FXaI's. The aim of this study was
to characterize anti-Xa levels in patients taking apixaban or … anti-Xa levels for apixaban and …
to characterize anti-Xa levels in patients taking apixaban or … anti-Xa levels for apixaban and …